Myelodysplastic Syndrome (MDS) Clinical Trials

Find Myelodysplastic Syndrome (MDS) Clinical Trials Near You

An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in Patients With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This study will test a study drug called REGN17235 (the study drug) to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well. * What is the best dose of the study drug to treat CCUS and LR-MDS

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Presence of SF3B1 mutation in the bone marrow or peripheral blood AND diagnosis of low-risk MDS OR diagnosis of CCUS as defined by WHO 2022, 5th edition as described in the protocol

• Adequate bone marrow function as described in the protocol; red blood cell transfusion dependence is permitted

• Adequate hepatic and renal function as described in the protocol

Locations
Other Locations
Belgium
Uz Ghent
RECRUITING
Ghent
Algemeen Ziekenhuis (AZ) Delta
RECRUITING
Roeselare
Contact Information
Primary
Clinical Trials Administrator
clinicaltrials@regeneron.com
844-734-6643
Time Frame
Start Date: 2026-09-17
Estimated Completion Date: 2031-05-05
Participants
Target number of participants: 52
Treatments
Experimental: Part 1 Dose Escalation
Experimental: Part 2 Safety Expansion
Related Therapeutic Areas
Sponsors
Leads: Regeneron Pharmaceuticals

This content was sourced from clinicaltrials.gov